[1] Defilippi A,Silvestri M,Tacchella A,et al.Epidemiology and clinical features of mycoplasma pneumoniae infection in children[J].Respir Med,2008,102(12):1726-1768. [2] 柯莉芹,王凤美,李银杰,等.儿童肺炎支原体肺炎流行病学特征[J].中国当代儿科杂志,2013,15(1):33-36. [3] Cosentini R,Tarsia P,Canetta C,et al.Severe asthma exacerbation:role of acute chlamydophila pneumoniae and mycoplasma pneumoniae infection [J].Respir Res,2008,9:48. [4] 江载芳.实用小儿呼吸病学[M].北京:人民卫生出版社,2010:240-246. [5] Noorbakhsh S,Farhadi M,Tabatabaei A,et al.Searching m -ycoplasma pneumonia by serology &PCR in children with adenoid hypertrophy and rhinosinusitis:A case control study,Tehran,Iran[J].Iran J Microbiol,2013,5(1):63-67. [6] Biondi E,McCulloh R,Alverson B,et al.Treatment of mycoplasma pneumonia:a systematic review[J].Pediatrics,2014,133(6):1081-1090. [7] 朱蕾.临床肺功能[M].北京:人民卫生出版社,2014. [8] 诸福棠.实用儿科学[M].北京:人民卫生出版社,2015. [9] 中华医学会儿科学会分会呼吸学组,中华儿科杂志编辑委员会.儿童社区获得性肺炎管理指南(2013年修订)上[J].中华儿科杂志,2013,51(10):745-752. [10] Kraft M,Cassell GH,Henson JE,et al.Detection of mycoplasma pneumoniae in the airways of adults with chronic asthma[J].Am J Respir Crit Care Med,1998,158(3):998-1001. [11] 魏云.咳嗽变异性哮喘与肺炎支原体感染关系的临床研究[J].中国当代医药,2012,19(7):91-92. [12] 朱炜春.支原体肺炎的治疗对气道高反应发生的影响[J].中国医药科学,2012,2(10):203-204. [13] Kannan TR,Jacqueline J,Coalson,et al.Synthesis and distribution of CARDS toxin during mycoplasma pneumoniae infection in a murine model[J].J Infect Dis,2011,204(10):1596-1604. [14] 孙红,孙红妹.肺炎支原体直接损伤及其免疫学致病机制研究进展[J].中华微生物学和免疫学杂志,2015,31(1):65-68. [15] Guilbert TW,Denlinger LC.Role of infection in the development and exacerbation of asthma [J].Expert Rev Respir Med,2010,4(1):71-83. [16] Hyvrinen M,Piippo-Savolainen E,Korhonen K,et al.Teenage asthma after severe infantile bronchiolitis or pneumonia[J].Acta Paediatr,2005,94(10):1378-1383. [17] 吴勇,蔡俊伟,李立浩,等.重症肺炎支原体肺炎患儿的肺功能变化及临床意义[J].吉林医学,2015,36(13):2743-2744. [18] 中华医学会儿科学会分会呼吸学组,临床儿科杂志编辑委员会.糖皮质激素雾化吸入疗法在儿科应用的专家共识[J].临床儿科杂志,2018,36(2):95-107. |